Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study
Open Access
- 5 May 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 6 (1), 118
- https://doi.org/10.1186/1471-2407-6-118
Abstract
Background Solitary plasmacytoma (SP) of the bone is a rare plasma-cell neoplasm. There are no conclusive data in the literature on the optimal radiation therapy (RT) dose in SP. Therefore, in this large retrospective study, we wanted to assess the outcome, prognostic factors, and the optimal RT dose in patients with SP. Methods Data from 206 patients with bone SP without evidence of multiple myeloma (MM) were collected. Histopathological diagnosis was obtained for all patients. The majority (n = 169) of the patients received RT alone; 32 chemotherapy and RT, and 5 surgery. Median follow-up was 54 months (7–245). Results Five-year overall survival, disease-free survival (DFS), and local control was 70%, 46%, and 88%; respectively. Median time to MM development was 21 months (2–135) with a 5-year probability of 51%. In multivariate analyses, favorable factors were younger age and tumor size < 5 cm for survival; younger age for DFS; anatomic localization (vertebra vs. other) for local control. Older age was the only predictor for MM. There was no dose-response relationship for doses 30 Gy or higher, even for larger tumors. Conclusion Younger patients, especially those with vertebral localization have the best outcome when treated with moderate-dose RT. Progression to MM remains the main problem. Further investigation should focus on adjuvant chemotherapy and/or novel therapeutic agents.Keywords
This publication has 39 references indexed in Scilit:
- Multiple myeloma in elderly patients: prognostic factors and outcomeEuropean Journal of Haematology, 2005
- Positron Emission Tomography (PET) for Staging of Solitary PlasmacytomaCancer Biotherapy & Radiopharmaceuticals, 2003
- Prognostic value of angiogenesis in solitary bone plasmacytomaBlood, 2003
- Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decadesEuropean Journal of Haematology, 1999
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)International Journal of Radiation Oncology*Biology*Physics, 1995
- The role of radiation therapy in the treatment of solitary plasmacytomasRadiotherapy and Oncology, 1990
- Extramedullary plasmacytomas and solitary plasma cell tumours of boneEuropean Journal of Haematology, 1990
- Solitary plasmacytoma of bone: mayo clinic experienceInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958